References

nogr

Экспериментальная и клиническая гастроэнтерология

Experimental and Clinical Gastroenterology

1682-8658

«Global Media Technologies»

10.31146/1682-8658-ecg-212-4-77-85

nogr-2365

Research Article

КЛИНИЧЕСКАЯ ГАСТРОЭНТЕРОЛОГИЯ

CLINICAL GASTROENTEROLOGY

Предикторы эффективности лечения хронического гепатита B аналогами нуклеоз(т)идов

Predictors of treatment efficacy with nucleos(t)ide analogues for chronic hepatitis B

https://orcid.org/0000-0003-0807-4736

Нгуен

Т. Х.

Nguyen

T. H.

drhanh@mail.ru

https://orcid.org/0000-0001-6029-1864

Ильченко

Л. Ю.

Ilchenko

L. Yu.

noemail@neicon.ru

https://orcid.org/0000-0001-8703-1982

Мельникова

Л. И.

Melnikova

L. I.

noemail@neicon.ru

https://orcid.org/0000-0002-3599-117X

Кюрегян

К. К.

Kyuregyan

K. K.

noemail@neicon.ru

https://orcid.org/0000-0002-4551-7535

Гордейчук

И. В.

Gordeychuk

I. V.

noemail@neicon.ru

Бондаренко

Н. Л.

Bondarenko

N. L.

noemail@neicon.ru

Федеральное государственное автономное образовательное учреждение высшего образования «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова» Министерства здравоохранения Российской ФедерацииРоссияPirogov Russian National Research Medical UniversityRussian Federation

Федеральное государственное автономное образовательное учреждение высшего образования «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова» Министерства здравоохранения Российской Федерации; Федеральное государственное автономное научное учреждение «Федеральный научный центр исследований и разработки иммунобиологических препаратов имени М. П. Чумакова» Министерства науки и высшего образования Российской Федерации, поселение Московский; Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт вакцин и сывороток им. И. И. Мечникова»РоссияPirogov Russian National Research Medical University; Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products of Russian Academy of Sciences; Mechnikov Research Institute of Vaccines and SeraRussian Federation

Федеральное государственное бюджетное учреждение здравоохранения «Клиническая больница № 85 Федерального медико-биологического агентства»РоссияClinical hospital № 85 FMBA of RussiaRussian Federation

Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт вакцин и сывороток им. И. И. Мечникова»РоссияMechnikov Research Institute of Vaccines and SeraRussian Federation

Федеральное государственное автономное научное учреждение «Федеральный научный центр исследований и разработки иммунобиологических препаратов имени М. П. Чумакова» Министерства науки и высшего образования Российской Федерации, поселение МосковскийРоссияChumakov Federal Scientific Center for Research and Development of Immune and Biological Products of Russian Academy of SciencesRussian Federation

2023

26072023

047785

2023

Нгуен Т.Х., Ильченко Л.Ю., Мельникова Л.И., Кюрегян К.К., Гордейчук И.В., Бондаренко Н.Л.

Nguyen T.H., Ilchenko L.Y., Melnikova L.I., Kyuregyan K.K., Gordeychuk I.V., Bondarenko N.L.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.nogr.org/jour/article/view/2365

Хроническая инфекция, вызванная вирусом гепатита В (HBV), остается глобальной проблемой здравоохранения. Пациенты с хронической HBV-инфекцией подвержены повышенному риску прогрессирования заболевания печени до цирроза и развития гепатоцеллюлярной карциномы (ГЦК). Основной целью терапии является улучшение качества жизни и выживаемости путем предотвращения прогрессирования заболевания до цирроза, ГЦК и смерти. Индукция долгосрочного подавления репликации HBV представляет собой важнейшую задачу текущих стратегий лечения, а клиренс поверхностного антигена гепатита В (HBsAg) является его оптимальной конечной точкой. Длительный прием мощных аналогов нуклеоз(т)идов (АН) с высоким барьером резистентности (энтекавира, тенофовира дизопроксил фумарата или тенофовира алафенамида) является терапией выбора. Однако факторы, ассоциированные с ответами на противовирусную терапию (ПВТ) АН, не ясны и не были включены в рекомендации по лечению. Цель данного обзора - обобщить результаты исследований, оценивающих влияние факторов на эффективность ПВТ АН. В исследовании рассмотрена значимость исходных факторов до начала лечения (демографических, гистологических, вирусологических, биохимических), а также динамических изменений вирусной нагрузки и уровня HBsAg во время проведения ПВТ в предсказании эффективности лечения.

Chronic hepatitis B virus (HBV) infection remains a global public health problem. Patients with chronic HBV infection are at increased risk of progression to cirrhosis and development of hepatocellular carcinoma (HCC). The primary goal of therapy is to improve quality of life and survival by preventing disease progression to cirrhosis, HCC, and death. Induction of long-term suppression of HBV replication represents the most important goal of current treatment strategies, and clearance of hepatitis B surface antigen (HBsAg) is its optimal endpoint. Long-term administration of potent nucleos(t)ides analogues (NA) with a high barrier to resistance (entecavir, tenofovir disoproxil fumarate, or tenofovir alafenamide) is the therapy of choice. However, factors associated with response to NA-based antiviral therapy (ART) are not clear and have not been included in treatment recommendations. The purpose of this review is to summarize the results of studies evaluating the influence of factors on the effectiveness of NA-based ART. The study examined the significance of baseline pre-treatment factors (demographic, histological, virological, biochemical) as well as dynamic changes in viral load and HBsAg levels during ART in predicting treatment efficacy.

противовирусная терапияпредикторыэффективностьвирусологический ответбиохимический ответклиренс HBsAgклиренс HBeAg

antiviral therapypredictorsefficacyvirologic responsebiochemical responseHBsAg clearanceHBeAg clearance

References1

World Health Organization. Hepatitis B Fact Sheet. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b Accessed 24 June 2022.

World Health Organization. Global hepatitis report, 2017. 2017: 83.

https://www.who.int/publications/i/item/9789241565455 Accessed 24 June 2022.

World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. World Health Organization. 2016. https://apps.who.int/iris/handle/10665/246177 Accessed 24 June 2022.

Howell J., Pedrana A., Schroeder S. E., et al. A global investment framework for the elimination of hepatitis B. Journal of hepatology. 2021;74(3):535-549. doi: 10.1016/j.jhep.2020.09.013.

European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of hepatology. 2017;67(2):370-398. doi: 10.1016/j.jhep.2017.03.021

Clinical guidelines Chronic viral hepatitis B (CHB) in adults Ministry of Health of the Russia. 2019: 70. (In Russ.)@@ Клинические рекомендации Хронический вирусный гепатит B (ХВГВ) у взрослых Минздрава РФ. 2019: 70 с.

Sriprayoon T., Mahidol C., Ungtrakul T., et al. Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: a randomized controlled trial. Hepatology Research. 2017;47(3): E161-E168. doi: 10.1111/hepr.12743.

Jeong S., Shin H. P., Kim H. I. Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.Intervirology. 2022;65(2):94-103. doi: 10.1159/000519440.

Huikun Z., Jiang J., Minghua S., et al. Efficacy of entecavir versus tenofovir disoproxil fumarate in treatment of chronic hepatitis B patients with high viral load. Journal of Clinical Hepatology. 2022;38(3):532-536. doi: 10.3969/j.issn.1001-5256.2022.03.008.

Chen M. B., Wang H., Zheng Q. H., et al.Comparative efficacy of tenofovir and entecavir in nucleos (t) ide analogue-naive chronic hepatitis B: a systematic review and meta-analysis. PloS one. 2019;14(11): e0224773. doi: 10.1371/journal.pone.0224773.

Cai D., Pan C., Yu W., et al.Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive HBeAg-positive patients with chronic hepatitis B: a large, multicentre, randomized controlled trials. Medicine. 2019;98(1). doi: 10.1097/MD. 0000000000013983.

Han Y., Zeng A., Liao H., et al. The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: a systematic review and meta-analysis.International Immunopharmacology. 2017;42:168-175. doi: 10.1016/j.intimp.2016.11.022.

Marcellin P., Wong D. K., Sievert W., et al. Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. Liver International. 2019;39(10):1868-1875. doi: 10.1111/liv.14155.

Hsu Y. C., Yeh M. L., Wong G. L.H., et al. Incidences and determinants of functional cure during entecavir or tenofovir disoproxil fumarate for chronic hepatitis B. The Journal of Infectious Diseases. 2021;224(11):1890-1899. doi: 10.1093/infdis/jiab241.

Hsu Y. C., Jun D. W., Peng C. Y., et al. Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort. Hepatology International. 2022:1-11. doi: 10.1007/s12072-022-10411-x.

Suzuki F., Hosaka T., Suzuki Y., et al. Long-term outcome of entecavir treatment of nucleos (t) ide analogue-naïve chronic hepatitis B patients in Japan. Journal of Gastroenterology. 2019;54(2):182-193. doi: 10.1007/s00535-018-1502-y.

Agarwal K., Brunetto M., Seto W. K., et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. Journal of hepatology. 2018;68(4):672-681. doi: 10.1016/j.jhep.2017.11.039.

Liang L. Y., Yip T. C.F., Lai J. C.T., et al. Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate. Journal of Medical Virology. 2022. doi: 10.1002/jmv.27863.

Hou J., Ning Q., Duan Z., et al. 3-year treatment of tenofovir alafenamide vs. Tenofovir disoproxil fumarate for chronic HBV infection in China. Journal of Clinical and Translational Hepatology. 2021;9(3):324. doi: 10.14218/JCTH.2020.00145.

Roade L., Riveiro-Barciela M., Esteban R., et al. Long-term efficacy and safety of nucleos (t) ides analogues in patients with chronic hepatitis B. Therapeutic Advances in Infectious Disease. 2021;8:2049936120985954. doi: 10.1177/204993612098595.

Marcellin P., Gane E., Buti M., et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. The Lancet. 2013;381(9865):468-475. doi: 10.1016/S0140-6736(12)61425-1.

Sun Y., Wu X., Zhou J., et al. Persistent low level of hepatitis B virus promotes fibrosis progression during therapy. Clinical Gastroenterology and Hepatology. 2020;18(11):2582-2591. e2586. doi: 10.1016/j.cgh.2020.03.001.

Singh S., Muir A. J., Dieterich D. T., et al. American Gastroenterological Association Institute technical review on the role of elastography in chronic liver diseases. Gastroenterology. 2017;152(6):1544-1577. doi: 10.1053/j.gastro.2017.03.016.

Facciorusso A., Perdomo H. A.G., Muscatiello N., et al. Systematic review with meta-analysis: change in liver stiffness during anti-viral therapy in patients with hepatitis B. Digestive and Liver Disease. 2018;50(8):787-794. doi: 10.1016/j.dld.2018.05.005.

Ibragimov E. K., Abdurakhmanov D. T., Rosina T. P., et al. Efficacy and safety of long-term therapy of chronic hepatitis B with nucleoside and nucleotide analogues. Therapeutic Archives. 2019;91(2):40-47. (In Russ.) doi: 10.26442/00403660.2019.02.000073.@@ Ибрагимов Э. К., Абдурахманов Д. Т., Розина Т. П., и соавт. Эффективность и безопасность длительной терапии хронического гепатита В нуклеозидными и нуклеотидными аналогами. Терапевтический архив. 2019;91(2):40-47. doi: 10.26442/00403660.2019.02.000073.

Ono A., Suzuki F., Kawamura Y., et al. Long-term continuous entecavir therapy in nucleos (t) ide-naïve chronic hepatitis B patients. Journal of hepatology. 2012;57(3):508-514. doi: 10.1016/j.jhep.2012.04.037.

Luo J., Li X., Wu Y., et al. Efficacy of entecavir treatment for up to 5 years in nucleos (t) ide-naïve chronic hepatitis B patients in real life.International journal of medical sciences. 2013;10(4):427. doi: 10.7150/ijms.5472.

Efremova O. S., Kozhevnikova G. M., Voznesensky S. L., et al. Effectiveness of modern nucleoside analogues in the treatment of patients with HbeAg-negative chronic hepatitis B. Infectious diseases. 2013;11(4):5-11. (In Russ.)@@ Ефремова О. С., Кожевникова Г. М., Вознесенский С. Л., и соавт. Эффективность современных нуклеозидных аналогов в лечении больных HbeAg-негативным хроническим гепатитом В. Инфекционные болезни. 2013;11(4):5-11.

Batirel A., Guclu E., Arslan F., et al.Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study.International Journal of Infectious Diseases. 2014;28:153-159. doi: 10.1016/j.ijid.2014.09.004.

Kayaaslan B., Akinci E., Ari A., et al. A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos (t) ide analogue-naive chronic hepatitis B patients. Clinics and research in hepatology and gastroenterology. 2018;42(1):40-47. doi: 10.1016/j.clinre.2017.06.008.

Jacobson I. M., Washington M. K., Buti M., et al. Factors associated with persistent increase in level of alanine aminotransferase in patients with chronic hepatitis B receiving oral antiviral therapy. Clinical Gastroenterology and Hepatology. 2017;15(7):1087-1094. e1082. doi: 10.1016/j.cgh.2017.01.032.

Xia Z., Zheng J., Zheng L., et al. Effects of dyslipidemia on E antigen seroconversion of patients with chronic hepatitis B treated by nucleoside (acid) analogs. Lipids in Health and Disease. 2021;20(1):1-10. doi: 10.1186/s12944-021-01582-x.

Lim S., Marcellin P., Tassopoulos N., et al. Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B. Alimentary pharmacology & therapeutics. 2007;26(10):1419-1428. doi: 10.1111/j.1365-2036.2007.03506.x.

Kim S. H., Cho E. J., Jang B. O., et al.Comparison of biochemical response during antiviral treatment in patients with chronic hepatitis B infection. Liver International. 2022;42(2):320-329. doi: 10.1111/liv.15086.

Charatcharoenwitthaya P., Pongpaibul A., Kaosombatwattana U., et al. The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response. Liver International. 2017;37(4):542-551. doi: 10.1111/liv.13271.

Zhang S., Zhang X., Jin H., et al. Adverse Effect of Nonalcoholic Fatty Liver Disease on the Therapeutic Response in Patients with Chronic Hepatitis B. Journal of Clinical and Translational Hepatology. 2023;11(1):67-75. doi: 10.14218/JCTH.2022.00066.

Park J. W., Kwak K. M., Kim S. E., et al.Comparison of the long-term efficacy between entecavir and tenofovir in treatment-naïve chronic hepatitis B patients. BMC gastroenterology. 2017;17(1):1-9. doi: 10.1186/s12876-017-0596-7.

Idilman R., Gunsar F., Koruk M., et al. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting. Journal of viral hepatitis. 2015;22(5):504-510. doi: 10.1111/jvh.12358.

Zheng Q., Zou B., Wu Y., et al. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B. Alimentary Pharmacology & Therapeutics. 2021;54(9):1100-1109. doi: 10.1111/apt.16595.

Mak L. Y., Hui R. W.H., Fung J., et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. Journal of hepatology. 2020;73(4):800-806. doi: 10.1016/j.jhep.2020.05.040.

Jin X., Chen Y. P., Yang Y. D., et al. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. PLoS One. 2012;7(3): e34198. doi: 10.1371/journal.pone.0034198.

Chang X. J., Shi Y. W., Wang J., et al. Influence of weight management on the prognosis of steatohepatitis in chronic hepatitis B patients during antiviral treatment. Hepatobiliary & Pancreatic Diseases International. 2021;20(5):416-425. doi: 10.1016/j.hbpd.2021.06.009.

Kim D. S., Jeon M. Y., Lee H. W., et al. Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir. Clinical and molecular hepatology. 2019;25(3):283-293. doi: 10.3350/cmh.2018.0054.

Chen Y. C., Jeng W. J., Hsu C. W., et al. Impact of hepatic steatosis on treatment response in nuclesos (t) ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study. BMC gastroenterology. 2020;20(1):1-9. doi: 10.1186/s12876-020-01289-w.

Myung H. J., Jeong S. H., Kim J. W., et al. Efficacy and predictors of the virologic response to entecavir therapy in nucleoside-naive patients with chronic hepatitis B. The Korean journal of hepatology. 2010;16(1):57-65. doi: 10.3350/kjhep.2010.16.1.57.

Cho J. Y., Sohn W., Sinn D. H., et al. Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response. The Korean journal of internal medicine. 2017;32(4):636. doi: 10.3904/kjim.2016.096.

Song J. E., Lee C. H., Kim B. S. Efficacy of long-term tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with partial virologic response in real practice. The Korean journal of internal medicine. 2019;34(4):802-810. doi: 10.3904/kjim.2019.037.

Lee J. M., Ahn S. H., Kim H. S., et al. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology. 2011;53(5):1486-1493. doi: 10.1002/hep.24221.

Lee M. H., Lee D. M., Kim S. S., et al. Correlation of serum hepatitis B surface antigen level with response to entecavir in naive patients with chronic hepatitis B. Journal of medical virology. 2011;83(7):1178-1186. doi: 10.1002/jmv.22089.

Marcellin P., Heathcote E. J., Buti M., et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. New England Journal of Medicine. 2008;359(23):2442-2455. doi: 10.1056/NEJMoa0802878.

Marcellin P., Buti M., Krastev Z., et al. Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. Journal of hepatology. 2014;61(6):1228-1237. doi: 10.1016/j.jhep.2014.07.019.

Inoue J., Akahane T., Nakayama H., et al.Comparison of hepatitis B virus genotypes B and C among chronically hepatitis B virus-infected patients who received nucleos (t) ide analogs: a multicenter retrospective study. Hepatology Research. 2019;49(11):1263-1274. doi: 10.1111/hepr.13398.

Berg T., Simon K.-G., Mauss S., et al. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients-FINITE study. Journal of hepatology. 2017;67(5):918-924. doi: 10.1016/j.jhep.2017.07.012.

Liem K. S., Fung S., Wong D. K., et al. Limited sustained response after stopping nucleos (t) ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study). Gut. 2019;68(12):2206-2213. doi: 10.1136/gutjnl-2019-318981.

Chen C. H., Hung C. H., Wang J. H., et al. Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients. Clinical Microbiology and Infection. 2018;24(9):997-1003. doi: 10.1016/j.cmi.2017.12.013.

Yao C. C., Hung C. H., Hu T. H., et al. Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg≤ 200 IU/mL. Scientific reports. 2017;7(1):1-9. doi: 10.1038/s41598-017-02010-w.

Chen C. H., Lu S. N., Hung C. H., et al. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. Journal of hepatology. 2014;61(3):515-522. doi: 10.1016/j.jhep.2014.04.029.

Bakhshizadeh F., Hekmat S., Keshvari M., et al. Efficacy of tenofovir disoproxil fumarate therapy in nucleoside-analogue naive Iranian patients treated for chronic hepatitis B. Hepatitis Monthly. 2015;15(5): e25749. doi: 10.5812/hepatmon.15(5)2015.25749.

Pan H. Y., Pan H. Y., Song W. Y., et al. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis. Journal of Viral Hepatitis. 2017;24:29-35. doi: 10.1111/jvh.12794.

Wen S. C., Tsai C. C., Cheng L. C., et al. Predictors of HBeAg loss after nucleos (t) ide analogues treatment for chronic hepatitis B: A preliminary finding. Advances in Digestive Medicine. 2021;8(1):10-18. doi: 10.1002/aid2.13190.

Buti M., Roade L., Riveiro-Barciela M., et al. Optimal management of chronic hepatitis B patients receiving nucleos (t) ide analogues. Liver International. 2020;40:15-21. doi: 10.1111/liv.14367.

Peng C. Y., Lai H. C., Su W. P., et al. Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B. Scientific reports. 2017;7(1):1-10. doi: 10.1038/srep42879.

Wang C. C., Tseng K. C., Hsieh T. Y., et al. Assessing the durability of entecavir-treated hepatitis B using quantitative HBsAg. Official journal of the American College of Gastroenterology| ACG. 2016;111(9):1286-1294. doi: 10.1038/ajg.2016.109.

Wang C. C., Kao J. H. The role of hepatitis B surface antigen in Nucleos (t) ide analogue cessation among Asian chronic hepatitis B patients: friend or foe? Hepatology. 2019;69(4):1843-1843. doi: 10.1002/hep.v69.4.

Jeng W. J., Chang M. L., Liaw Y. F. Off-therapy precipitous HBsAg decline predicts HBsAg loss after finite entecavir therapy in HBeAg-negative patients. Journal of Viral Hepatitis. 2019;26(8):1019-1026. doi: 10.1111/jvh.13114.

Jeng W. J., Chen Y. C., Chien R. N., et al. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos (t) ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2018;68(2):425-434. doi: 10.1002/hep.29640.

Liu J., Li T., Zhang L., et al. The role of hepatitis B surface antigen in nucleos (t) ide analogues cessation among asian patients with chronic hepatitis B: a systematic review. Hepatology. 2019;70(3):1045-1055. doi: 10.1002/hep.30474.

Chien N. H., Huang Y. T., Wu C. Y., et al. Time-varying serum gradient of hepatitis B surface antigen predicts risk of relapses after off-NA therapy. BMC gastroenterology. 2017;17(1):1-7. doi: 10.1186/s12876-017-0697-3.

The authors declare that there are no conflicts of interest present.